Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Joëlle Raschle"'
Autor:
Ilka Rüsges-Wolter, Thomas Pabst, Joëlle Raschle, Isabelle von Grünigen, Behrouz Mansouri Taleghani, Beatrice U. Mueller
Publikováno v:
Leukemia research
Autologous stem cell transplantation (ASCT) is widely used to consolidate first remission in AML. We determined the significance of circulating CD34+ cells at the day of blood stem cell collection in 78 AML patients. Patients mobilizing more than 60,
Autor:
Joëlle Raschle
Publikováno v:
Praxis. 106:677-678
Autor:
Joëlle Raschle
Publikováno v:
Praxis. 106:433-434
Publikováno v:
British Journal of Cancer
Background: High-dose chemotherapy with autologous stem cell transplantation is a cornerstone in the first-line treatment of multiple myeloma patients. However, only few factors have been identified affecting the outcome in such patients. We hypothes
Publikováno v:
Swiss medical weekly
Raschle, Joëlle; Banz Wälti, Yara; Suter, Thomas; Pabst, Thomas (2014). A single-centre cohort of patients with systemic light chain AL-amyloidosis treated with conventional chemotherapy or with high-dose chemotherapy and autologous stem cell transplantation. Swiss medical weekly, 144, w13922. EMH Schweizerischer Ärzteverlag 10.4414/smw.2014.13922
Raschle, Joëlle; Banz Wälti, Yara; Suter, Thomas; Pabst, Thomas (2014). A single-centre cohort of patients with systemic light chain AL-amyloidosis treated with conventional chemotherapy or with high-dose chemotherapy and autologous stem cell transplantation. Swiss medical weekly, 144, w13922. EMH Schweizerischer Ärzteverlag 10.4414/smw.2014.13922
BACKGROUND High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) has been reported to confer better prognosis in systemic light chain AL-amyloidosis as compared with conventional chemotherapy. However, only limited data are a